At Cedar, we believe in the vision that population health and welfare are enhanced by the development and diffusion of innovative healthcare technologies.
To promote this vision, we conduct evidence-based research on the comparative value of health care technologies. For the past two decades, our research has paved the way for breakthrough drugs, devices, and diagnostics to play effective roles in various health care settings.
Our leadership has a unique blend of experience that combines medical and academic training with a pragmatic understanding of challenges of research, and best practices for innovation adoption. Success hinges on a collaborative model, which we find includes payers, providers, key opinion leaders, and medical policy organizations.
Cedar’s publication, Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph node-negative, estrogen receptor-positive, early stage breast cancer, was cited in an amicus brief presented to the U.S. Supreme Court by the Biotechnology Industry Organization to substantiate the value of personalized medicine and the need for patent protection for novel diagnostic technologies.